Advertisement

Topics

CEL-SCI Gives Update on Partial Clinical Hold on Phase 3 Head and Neck Cancer Study with Multikine

08:00 EST 6 Mar 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
CEL-SCI Corporation (NYSE MKT: CVM) announces that it has received the official minutes from its February 8, 2017 meeting with the U.S. Food and Drug Administration (FDA) in regards to the partial clinical hold placed on the Pha...

Other Sources for this Article

CEL-SCI Corporation
Gavin de Windt, 703-506-9460

NEXT ARTICLE

More From BioPortfolio on "CEL-SCI Gives Update on Partial Clinical Hold on Phase 3 Head and Neck Cancer Study with Multikine"

Advertisement
Quick Search
Advertisement
Advertisement